The US FDA is weighing whether patents covering digital applications used with approved drugs should be listed in the “Orange Book” as part of the agency’s efforts to modernize the compendium.
In a Jan. 30 announcement about new guidance and other initiatives aimed at making the Orange Book a more useful...